Movatterモバイル変換


[0]ホーム

URL:


EP1590041B1 - Treatment of periodontal disease with photosensitizers - Google Patents

Treatment of periodontal disease with photosensitizers
Download PDF

Info

Publication number
EP1590041B1
EP1590041B1EP03754493.9AEP03754493AEP1590041B1EP 1590041 B1EP1590041 B1EP 1590041B1EP 03754493 AEP03754493 AEP 03754493AEP 1590041 B1EP1590041 B1EP 1590041B1
Authority
EP
European Patent Office
Prior art keywords
photosensitizer
treatment
diseases
composition
oral cavity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03754493.9A
Other languages
German (de)
French (fr)
Other versions
EP1590041A4 (en
EP1590041A2 (en
Inventor
Wolfgang Neuberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec Pharma IP & Investment Ltd
Original Assignee
Biolitec Pharma IP & Investment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec Pharma IP & Investment LtdfiledCriticalBiolitec Pharma IP & Investment Ltd
Publication of EP1590041A2publicationCriticalpatent/EP1590041A2/en
Publication of EP1590041A4publicationCriticalpatent/EP1590041A4/en
Application grantedgrantedCritical
Publication of EP1590041B1publicationCriticalpatent/EP1590041B1/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Description

    Background of the invention1. Field of the invention
  • The present invention relates to the use of photosensitizing compounds in long term effect or timed release formulations and laser irradiation to kill the microbes involved in a number of oral diseases including inflammatory periodontal disease.
  • 2. Information Disclosure Statement
  • Advanced periodontal disease is one of a large number of oral infectious diseases, and is the principal cause of tooth loss in those over 30 years old. The term "periodontal disease" actually encompasses a number of diseases that affect the supporting tissues of the teeth. The periodontium consists of the investing and supporting tissues of the tooth, and consists of the gingiva, the periodontal ligament, the cementum and the alveolar bone. The periodontium is subject to morphological and functional variations associated with age and pathology. The term gingivitis refers to an inflammation of the gingival tissue. Recent research on periodontal disease shows that not all patients with gingivitis progress to periodontal disease. However, gingivitis may be the first sign of oncoming periodontal disease and most, if not all, periodontal disease features accompanying gingivitis. Periodontitis is defined as inflammation involving the gingival unit (gingiva and alveolar mucosa) and extends to the periodontal ligament, alveolar bone, and cementum. Periodontitis is characterized by loss of clinical attachment of the gingiva and radiographic loss of bone.
  • The vast body of evidence indicates that the primary cause of both gingivitis and periodontitis is bacterial activity. Bacteria attach to the tooth surface at and slightly under the gingival margin. They colonize and form an organized mass that is referred to as bacterial plaque. This plaque, if allowed to remain, brings about inflammatory changes in the tissues. The pathogenic potential of plaque can vary from one individual to another and from tooth to tooth within an individual. The reaction of the host tissues to this bacterial attack is through an inflammatory and immunologic defense mechanism. Periodontal diseases arise from the interaction between bacterial cells and their products in dental plaque and the host defense mechanisms.
  • A variety of treatment modalities have been utilized to combat the disease and prevent its progression. Periodontal surgery is one such modality, and it includes curettage, gingivectomy, and flap or pocket elimination including the modified Widman flap procedure. Chemotherapy is also used, particularly local and systemic antibiotic treatment. The antibiotic agents most frequently used in chemotherapy for periodontal disease are the tetracyclines and metronidazole.
  • The conventional methods described above suffer from a number of significant drawbacks. Surgical reduction of periodontal pockets can expose roots, cause sensitivity, and result in poor aesthetics by lengthening the clinical crown and altering the gingival contours. Surgical treatment does not guarantee that the disease process will not recur to the detriment of the patient's dentition. It is reported that to treat periodontitis the effective concentration of antibiotics such as minocycline HCl must be maintained for at least 7 to 10 days.
  • According toU.S. Patent No. 5,599,553, it is reported that a pharmaceutical preparation composed of minocycline HCl and polycaprolactone in the form of a delivery film can release the active substance for 7 days in the periodontal pocket. However, in this case polycaprolactone must be completely removed after the drug is released because it takes too long to decompose in the body. This problem can be overcome by a formulation for treating periodontitis using biodegradable microspheres which retain an effective drug concentration in the periodontal pocket for a certain time after a single dose. There is no discomfort due to the feeling of a foreign substance because the formulation is prepared with microparticles, and there is no need to remove the formulation after treatment because it is biodegradable. However, these improvements do not address the need for repeated treatments, since the dental disease is generally chronic.
  • However, antibiotic therapy is usually not totally successful, particularly in advanced cases, probably because the site of action of periodontal disease is not accessible to a sufficient concentration of drug at the base of the periodontal pocket to completely halt the disease process. Moreover, the long-term use of antimicrobial agents, such as chlorhexidine and tetracycline, promote the development of resistance which render the agents clinically ineffective and can also disturb the oral microflora. Anti-microbial solutions have been introduced through irrigating devices to the periodontal pocket with some success, but are not curative. Sustained systemic administration of antibiotics such as tetracyclines is inadvisable because of the potentially serious side effects and the possibility of giving rise to antibiotic-resistant infections. New, more effective approaches to the treatment of periodontal disease, particularly periodontitis, are actively being sought.
  • Photodynamic therapy (PDT) has been proposed as an attractive method of eliminating oral bacteria and bacteria in topical and gastrointestinal infections because these sites are relatively accessible to illumination. For example, Wilson and Harvey proposed inU.S. Patent No. 5,611,793 the use of photosensitizers in combination with suitable irradiation to treat several oral diseases. However, this method suffers from the fact that the duration of the treatment is not sufficient. To treat periodontitis, effective concentration of the active substance in the periodontal pocket must be maintained for a relatively long time.
  • WO 9839011 A1 discloses a method of treatement of a disorder characterized by the presence of an unwanted bacterium in the oral cavity, comprising administering a photosensitizer conjugate and providing iridiation to produce a phototoxic effect by the photosensitizer.
  • It would be useful to provide a method of treatment for periodontitis which overcomes the drawbacks of prior art methods and further may be practiced or continued by patients at home as well as utilized by professional dental practitioners. The present invention address this need.
  • Brief Summary and Objectives of the Invention
  • The present invention is directed to a time-release photosensitizer composition according to claim 1.
  • It is an object of the present invention to provide a method for treatment of oral diseases characterized by long duration.
  • It is another object of the present invention to use photodynamic therapy (PDT) for the treatment of oral diseases with photosensitizers applied in a timed release formulation or coating at the desired sites.
  • It is a further object of the present invention to activate the photosensitizers by irradiation at suitable wavelengths with light, applied either by the dentist or as repeated treatment by the patient at home e.g. using a laser toothbrush.
  • It is a still further object of the present invention to modify the photosensitizer to more effectively target the photosensitizer to the unwanted (bacterial) species.
  • Briefly stated, the present invention discloses a method and composition for treating oral diseases, including inflammatory periodontal disease, by utilizing photosensitizing compounds in long term effect or timed release formulations, including local highly concentrated formulations in biofilms on teeth and implants and oral wounds as well as periodontal pockets, and activating the photosensitizers with radiation to selectively destroy bacteria and other microbial bodies. Photosensitizers are incorporated in a timed release formulation characterized by release of photosensitizers over a prolonged period of time. The photosensitizers are housed within micro- or nanoparticles, and can be gradually released through biodegradation or periodically released by such processes as brushing, irradiation and chemically induced release. The diffusion speed of the photosensitizers can be accelerated by brushing. The formulation is applied to the oral cavity and allowed to settle on biofilms therein, in periodontal pockets formed by the disease, or coated at the desired sites. Released photosensitizers are activated by radiation of preselected wavelengths in one or repeated treatments which can be carried out either by a dental professional or as a repeated treatment by the patient at home with, for example, a laser toothbrush. In another embodiment, the photosensitizer molecule is also modified to more effectively target the molecule to the unwanted oral bacterial species. The present invention has further use in that the micro- or nanoparticles act to protect photosensitizers from inactivation or degradation by saliva or other body fluids.
  • The above, and other objects, features and advantages of the present invention will become apparent from the following description.
  • Detailed Description of Preferred Embodiments
  • The present invention provides a composition for disinfecting or sterilizing tissues in the oral cavity or a wound or lesion in the oral cavity. Also disclosed is a method that comprises applying a photosensitizing compound in a timed release formulation, as well as a formulation which provides locally high concentrations of primary protected photosensitizers, to the tissues, wound or lesion. Photosensitizers that produce highly reactive singlet oxygen upon activation by irradiation are known to be effective in destroying unwanted (bacterial) species and thereby disinfecting and sterilizing lesions and wounds as well as implants in the oral cavity. The timed release is characterized by providing a sustained concentration of the photosensitizer in or around a treatment area during a prolonged time period in which the photosensitizer can be activated one or several times by irradiating the tissues, wound or lesion with laser light at a wavelength absorbed by the photosensitizing compound.
  • This long term formulation is characterized by its ability to maintain a certain concentration of the photosensitizer drug over a prolonged period of time, and it thus provides the ability to repeatedly activate the photosensitive compound after a single application and thereby achieve healing due to repeated treatments over an extended time period with only one application of the formulation. The photosensitive molecules are included in and released from micro- or nanoparticles by controlled diffusion. Biodegradable nanoparticles can be used to avoid the step of actively releasing the molecules. In that case, the duration of the timed release would be limited and would vary depending on the composition of the nanoparticles. In another embodiment, release from some or all of the micro- or nanoparticles can be actively and controllably induced by the user or practitioner as part of the treatment.
  • These formulations are especially useful in treating chronic diseases like periodontal lesions where repeated treatments are necessary to achieve healing. After a photosensitizer in a timed release formulation is administered to the affected area, it is left in contact with the microbes for a period of time to enable the microbes to take up some of the photosensitizer and become sensitive to the laser light. The photosensitizers are subsequently activated by radiation at suitable wavelengths for one or more treatments to destroy the target microbes. The activation can be carried out by a dental practitioner or even by the patient at home with, for example, a laser toothbrush.
  • In preferred aspects of the invention, the described treatment with photosensitizing compounds and laser irradiation can be applied to a variety of tasks including:
    • the destruction of disease-related microbes in a periodontal pocket in order to treat chronic periodontitis;
    • the destruction of disease-related microbes in the region between the tooth and gingiva (gingival crevice or gingival margin) in order to treat or prevent inflammatory periodontal diseases including chronic periodontitis, gingivitis and the like; and
    • the disinfection or sterilization of dental implants and dental and/or gingival tissues in other dental surgical procedures.
  • The advantage of the use of photosensitive compounds over other methods, such as antibiotic treatments, is the ability to controllably activate the compound with radiation and therefore enhance treatment effects. The long term use of antibiotics often promotes the development of resistance rendering the agents clinically ineffective and also disturbs the oral microflora. Additionally, high concentrations of antibiotics may have undesired side effects in the tissue and on the oral microflora. Since the photosensitive compound shows no toxicity without irradiation, the application of high concentrations and short and possibly repeated activation times show enhanced therapeutic effects and reduced side effects. High concentrations of the photosensitizer can be achieved, for example, by the use of specialized micro- and nano-particles such as dendrimers. Moreover, the ability of the compound to destroy only the unwanted species and leave healthy tissue intact can be enhanced by modifying the compound with targeting moieties. These modifications can affect chemical or physical properties that show an affinity to areas such as the cell membranes of unwanted bacterial species. Other targeting methods including coupling with antibodies or other affinity molecules are conceivable.
  • It is preferred that the photosensitizers used in the method of the present invention are activatable by light at the red end of the visible spectrum or at longer wavelengths, preferably between 630 and 800 nm. Light at these wavelengths is better able to penetrate tissues surrounding a wound or lesion, such as oral tissues, and, in particular, blood which may be present in the sites to be treated. This may be particularly useful in treating Alcove-like regions having honeycomb-like pockets. Several "second generation" photosensitive compounds with these spectral absorption properties are known to date, and include porphyrins, porphyrin derivatives, chlorins, pheophorbides, bacteriopheophorbides, phthalocyanines, naphthalocyanines, thiazines, xanthenes, pyrrylium dyes, psoralens, quinones. Also disclosed are photosensitizer precursors such as amenolevulic acid (ALA).
  • The timed release characteristic of the present formulation is due to the inclusion of polymeric micro- or nanoparticles, constructed with polymers, that contain the photosensitizer molecules. Release of photosensitizers from these polymers can occur by two general mechanisms. The first mechanism is diffusion resulting in the gradual release of the photosensitive molecules from the implant surface. The second mode of release occurs by the cleavage of the polymer backbone, defined as bulk erosion. Release can also be induced by a number of other processes. Such processes include radiation, ultrasonics, agitation through brushing, and chemical release such as with a solvent.
  • The micro- or nanoparticles consist of molecules building up polymers that are tolerable and non-toxic to the human or animal body. Several such compositions are known to date, among them are biodegradable and non-degradable compositions. Non-degradable particles must be removed after a certain time and thus the duration of the deposit effect can be chosen. The life time of biodegradable compounds is limited but can be chosen in a certain range by varying the composition and size of the polymer. The molecular weight of the polymers has an important effect on the period of drug release and degradation of the microspheres. The products of degradation processes such as hydrolysis of the particles are biologically compatible and metabolizable moieties which are eventually removed from the body. Polymer biodegradation products are formed at a very slow rate, and hence do not affect normal cell function. Moreover, the deposit effect can be achieved by coating the affected areas such as teeth, implants or periodontal pockets with the photosensitizer.
  • In addition to the advantage of being able to house and gradually or periodically release photosensitizers, nanoparticles offer an additional benefit. Many photosensitizers suffer from significant inhibition in effectiveness from exposure to saliva, white blood cells, and other natural defenses in the mouth. This can prove a significant problem in maintaining an effective concentration of photosensitizers in the mouth for an extended period of time. Because photosensitizers are encased in nanoparticles before treatment, they are shielded from these bodily fluids and thus do not degrade as quickly as they would if left unprotected. Non-biodegradable micro- or nanoparticles serve to protect photosensitizers until the photosensitizers are released. Likewise, biodegradable nanoparticles also protect photosensitizers until they degrade to the point where they release the photosensitizers. In this way, micro- or nanoparticles further serve to prolong the period of time that photosensitizers can remain in the oral cavity.
  • It should be noted that the photosensitizer has to be in a certain concentration at the site of treatment and, for instance in the treatment of periodontal pockets and wounds where the treatment site may be flooded with body fluid such as saliva or blood, it might be necessary to apply the photosensitizers in greater concentration so as to achieve an effective concentration after dilution by the body fluid. Moreover, the treatment is more effective if the photosensitizer is applied in higher concentrations. These concentrations can be achieved by using highly specialized micro- and nanoparticles like dendrimer-photosensitizer complexes. Since the photosensitive compounds do not show any dark toxicity, these concentrations can be applied without side effects. Because exposure of the surrounding tissues of the oral cavity to the activated photosensitizer will generally be of short duration and highly localized, it may also be acceptable to use compounds which have some slight toxicity to these tissues.
  • It is a further object of the present invention to enhance the selectivity of the timed release photosensitizer towards unwanted species such as bacteria. The targeting is either achieved by chemically modifying the chemical or physical properties of the photosensitizer, or by coupling the molecule to a targeting moiety such as an antibody. It is generally preferred that the photosensitizer selected for use has a positive charge under physiological conditions since such photosensitizers are more readily taken up by the target microbes. Other targeting moieties that specifically recognize components of the bacterial cell membranes are known.
  • The present invention is further illustrated by the following examples, but is not limited thereby.
  • Example 1: Bacterial redcution in biofilms within the oral cavity.
  • A dentist or patient can treat periodontal disease in various stages, or self-apply the treatment for prevention of diseases arising from microbes within the oral cavity.. A composition containing photosensitizers encased in micro- or nanoparticles is administered either by a dentist or by the patient. For patient application, a mouthwash is used containing a high concentration of the nanoparticles. The patient takes a prescribed dose of the mouthwash, and apply it as one would apply traditional mouthwashes to coat the mouth. Patient would then wait a prescribed period, typically 4 to 6 hours, or apply the mouthwash before bedtime. During this time, the mouth's natural saliva would serve to flush most of the micro- or nanoparticles from the mouth, leaving only those particle which are associated with the biofilms or trapped in existing periodontal pockets. After the prescribed period, the dentist/patient would then administer radiation using a laser toothbrush (as seen in, for example,U.S. Patent No. 5,658,148) to apply laser radiation for a prescribed duration or other means to direct irradiation to the treated sites within the oral cavity. The application would be similar in duration to the time taken to brush one's teeth. A prescribed frequency of about 2 times a day would effectively destroy harmful bacteria in the mouth.
  • Example 2: Periodontal pocket treatment for disease.
  • A dental practitioner applies the photosensitizer formulation. A gel containing the above-described micor- or nanoparticles is applied by the dentist directly to the periodontal pockets. This is preferable for patients with more advanced stages of periodontal disease, in that the dentist can insure that sufficient photosensitizer reaches the deeper pockets. In one preferred embodiment the gel is chosen to harden after application, so that photosensitizer is set to slowly release over an extended period of time such as days/weeks etc. The pockets themselves should act to contain the photosenstizer for an extended period of time. The patient returns for periodic radiation treatments or in an alternative case self-applies radiation at prescribed intervals as described in Example 1 using a laser toothbrush, as mentioned above, or other suitable means.

Claims (14)

  1. A time-release photosensitizer composition for use in the treatment of diseases of the oral cavity comprising the steps of:
    a. administering a photosensitizer to an area needing treatment in a timed release formulation, wherein said timed release formulation controllably releases said photosensitizer to treatment sites; and
    b. activating said photosensitizer by irradiating said area needing treatment at preselected wavelengths to reduce bacteria at that treatment area,
    - wherein said photosensitizer is a photosensitive molecule selected from a group consisting of porphyrins, chlorins, pheophorbides, bacteriopheophorbides, phthalocyanines, naphthalocyanines, thiazines, xanthenes, pyrrylium dyes, psoralens, and quinones,
    - further comprising micro- or nanoparticles that encase said photosensitizer, and wherein said timed release is achieved by controlled release of said photosensitizer from said micro- or nanoparticles,
    - wherein said photosensitizer is activated by irradiating repeatedly at predetermined intervals, which range from a period of hours to days.
  2. The composition for use in the treatment of diseases of the oral cavity according to claim 1,
    for treating periodontal pockets.
  3. The composition for use in the treatment of diseases of the oral cavity according to claim 1,
    for treating bacterial biofilms on teeth, on implants or in wounds.
  4. The composition for use in the treatment of diseases of the oral cavity according to claim 1,
    wherein said micro- or nanoparticles are biodegradable particles.
  5. The composition for use in the treatment of diseases of the oral cavity according to any of claims 1 to 4,
    wherein said timed release is achieved by periodically actively releasing said photosensitizer from a portion of said micro- or nanoparticles, wherein said method of actively releasing is selected from a group consisting of bulk erosion, radiation, ultrasonics, agitation through brushing, biochemical/enzymatic release, and chemical release.
  6. The composition for use in the treatment of diseases of the oral cavity according to claim 5,
    wherein said releasing by chemical release is by applying a solvent.
  7. The composition for use in the treatment of diseases of the oral cavity according to claim 1,
    for said administering of said photosensitizer in a formulation selected from a group consisting of direct application, application with a mouthwash, application with a gel, and application with a hardening gel.
  8. The composition for use in the treatment of diseases of the oral cavity according to claim 1,
    wherein said photosensitizer is activated by an irradiating step at preselected wavelengths between 630 and 800 nm.
  9. The composition for use in the treatment of diseases of the oral cavity according to claim 8,
    wherein said timed release formulation comprises a concentration of photosensitizer which allows repeated irradiation at predetermined intervals without additional applications of said composition.
  10. The composition for use in the treatment of diseases of the oral cavity according to any of claims 1 to 9,
    wherein said photosensitizer is a known photosensitizer precursor and wherein said photosensitizer precursor is aminolevulinic acid.
  11. The composition for use in the treatment of diseases of the oral cavity according to claim 4 or 5,
    wherein said photosensitizer comprises micro-or nanoparticle complexes to achieve high concentrations of said photosensitizer at a treatment area which can be activated by one or more irradiations.
  12. The composition for use in the treatment of diseases of the oral cavity according to claim 11,
    wherein said micro- or nanoparticle complexes are dendrimer-photosensitizer complexes.
  13. The composition for use in the treatment of diseases of the oral cavity according to any one of claims 1 to 3,
    wherein said photosensitizer comprises a modified photosensitizer complex having antibodies attached to said photosensitizer complex.
  14. The composition for use in the treatment of diseases of the oral cavity according to any one of claims 1 to 3,
    wherein said photosensitizer comprises a modified photosensitizer complex having molecular fragments attached to said photosensitizer complex, able to target components of bacterial cell membrane.
EP03754493.9A2002-09-122003-09-11Treatment of periodontal disease with photosensitizersExpired - LifetimeEP1590041B1 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US2419582002-09-12
US10/241,958US20040052798A1 (en)2002-09-122002-09-12Microbe reduction in the oral cavity with photosensitizers
PCT/US2003/028455WO2004024080A2 (en)2002-09-122003-09-11Treatment of periodontal disease with photosensitizers

Publications (3)

Publication NumberPublication Date
EP1590041A2 EP1590041A2 (en)2005-11-02
EP1590041A4 EP1590041A4 (en)2011-03-16
EP1590041B1true EP1590041B1 (en)2015-07-01

Family

ID=31991295

Family Applications (1)

Application NumberTitlePriority DateFiling Date
EP03754493.9AExpired - LifetimeEP1590041B1 (en)2002-09-122003-09-11Treatment of periodontal disease with photosensitizers

Country Status (4)

CountryLink
US (1)US20040052798A1 (en)
EP (1)EP1590041B1 (en)
AU (1)AU2003272317A1 (en)
WO (1)WO2004024080A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20080069781A1 (en)*2006-09-192008-03-20Ceramoptec Industries Inc.Treatment of periodontal disease with photosensitizers
US20050053895A1 (en)2003-09-092005-03-10The Procter & Gamble Company Attention: Chief Patent CounselIlluminated electric toothbrushes emitting high luminous intensity toothbrush
ES2401148T3 (en)*2004-04-162013-04-17Bredent Medical Gmbh & Co. Kg Preparation to photodynamically combat microorganisms and use of the preparation
CA2605551A1 (en)*2005-05-102006-11-16Naomi BalabanCompositions for administering rnaiii-inhibiting peptides
RU2008129887A (en)*2006-02-172010-03-27Дзе Проктер Энд Гэмбл Компани (US) METHOD OF INFLUENCE ON MICRO-ORGANISMS IN THE ORAL CAVITY
US20090035725A1 (en)*2007-08-022009-02-05Ondine International, Ltd.Photodisinfection of oral cavity
US9642687B2 (en)2010-06-152017-05-09The Procter & Gamble CompanyMethods for whitening teeth
DE102011075808B4 (en)*2010-09-102017-06-29Biolitec Ag Implant for use in a photo-dynamic treatment and method for producing the implant
US12109429B2 (en)2015-07-282024-10-08Know Bio, LlcPhototherapeutic light for treatment of pathogens
CN111701144B (en)2015-07-282023-03-21诺欧生物有限责任公司Systems and methods for phototherapy modulation of nitric oxide
FI130369B (en)2018-10-262023-07-28Koite Health Oy Procedure for treatment of biological surfaces
US12011611B2 (en)2020-03-192024-06-18Know Bio, LlcIllumination devices for inducing biological effects
US11147984B2 (en)2020-03-192021-10-19Know Bio, LlcIllumination devices for inducing biological effects
US11986666B2 (en)2020-03-192024-05-21Know Bio, LlcIllumination devices for inducing biological effects
US12347337B2 (en)2020-12-102025-07-01Know Bio, LlcEnhanced testing and characterization techniques for phototherapeutic light treatments
US11654294B2 (en)2021-03-152023-05-23Know Bio, LlcIntranasal illumination devices
US12115384B2 (en)2021-03-152024-10-15Know Bio, LlcDevices and methods for illuminating tissue to induce biological effects
CN114272152B (en)*2021-12-092023-10-31哈尔滨工业大学(深圳)Photosensitizers for tooth biofilm inhibition and tooth whitening by combining photodynamic method
CN119174740B (en)*2024-11-262025-02-11吉林大学 Preparation method and application of multifunctional nanospheres targeting bacteria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU629316B2 (en)*1990-04-111992-10-01Flora Inc.Periodontal disease treatment system
WO1993021992A1 (en)*1992-04-301993-11-11Institute Of Dental SurgeryLaser treatment
KR950007907B1 (en)*1992-09-011995-07-21동국제약 주식회사Pharmaceutical preparation for dental use
US5658148A (en)*1995-04-261997-08-19Ceramoptec Industries, Inc.Dental laser brushing or cleaning device
US6056548A (en)*1995-04-262000-05-02Ceramoptec Industries, Inc.Hygienic dental laser photo treatment method
US6462070B1 (en)*1997-03-062002-10-08The General Hospital CorporationPhotosensitizer conjugates for pathogen targeting
US6562295B1 (en)*1999-06-302003-05-13Ceramoptec Industries, Inc.Bacteria resistant medical devices
JP4177532B2 (en)*1999-10-082008-11-05宏子 垰田 Plaque control toothpaste and toothbrush
US6589562B1 (en)*2000-10-252003-07-08Salvona L.L.C.Multicomponent biodegradable bioadhesive controlled release system for oral care products
US20020127224A1 (en)*2001-03-022002-09-12James ChenUse of photoluminescent nanoparticles for photodynamic therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMUS: "Photosensitizing agents", 7 February 2011 (2011-02-07), pages 1, Retrieved from the Internet <URL:htttp:/www.ncbi.nlm.nih.gov/mesh/68017319> [retrieved on 20110207]*
GRANT W E ET AL: "Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 342, 17 July 1993 (1993-07-17), pages 147 - 148, XP002132811, ISSN: 0140-6736, DOI: 10.1016/0140-6736(93)91347-O*

Also Published As

Publication numberPublication date
EP1590041A4 (en)2011-03-16
WO2004024080A3 (en)2004-08-26
AU2003272317A1 (en)2004-04-30
AU2003272317A8 (en)2004-04-30
US20040052798A1 (en)2004-03-18
EP1590041A2 (en)2005-11-02
WO2004024080A2 (en)2004-03-25

Similar Documents

PublicationPublication DateTitle
EP1590041B1 (en)Treatment of periodontal disease with photosensitizers
US20080069781A1 (en)Treatment of periodontal disease with photosensitizers
JP4943149B2 (en) Antibacterial photodynamic therapeutic compounds based on erythrosin and methods of use thereof
Naik et al.Ozone-a biological therapy in dentistry-reality or myth?????
CN1658806A (en)Method and tools for oral hygiene
US20100100030A1 (en)Microbe Reductions with Photosensitizers
WO2009018205A1 (en)Photodisinfection of oral cavity
Amaral et al.Antimicrobial photodynamic therapy associated with long term success in endodontic treatment with separated instruments: a case report
Makkar et al.Ozone-treating dental infections
US20120189710A1 (en)Antibacterial compositions
Pourhajibagher et al.Application of photosensitive dental materials as a novel antimicrobial option in dentistry: A literature review
Mirhashemi et al.Evaluation of the photodynamic therapy with riboflavin and curcumin on shear bond strength of orthodontic bracket: An in vitro study
Alpan et al.Ozone in dentistry
RU2522211C1 (en)Method of treating periodontitis
Tapashetti et al.Photodynamic Therapy in Periodontics
Chiniforush et al.Antimicrobial photodynamic therapy for periodontal and peri-implant disease
Khurana et al.Photodynamic therapy-A ray towards periodontics
KR20070017292A (en) Erythrosine-Based Antimicrobial Photodynamic Therapeutic Compounds and Uses thereof
Tanka et al.Surgical management of peri-implantitis in adjunction with BlueM oxygen therapy: a case report with 5-years follow-up
Khan et al.Photodynamic therapy: A targeted therapy in periodontics
CN115245566B (en)Application of mesoporous silicon-loaded nitrogen-doped graphene nanocomposite in preparation of photo-thermal periodontitis treatment drug and preparation method
Бойцанюк et al.CURRENT TENDENCIES IN NON-SURGICAL PERIODONTAL TREATMENT. LITERATURE REVIEW
Coluzzi et al.Laser Treatment of Periodontal and Peri-implant Disease
Dushkin et al.Exploring Therapeutic Outcomes of Photodynamic Therapy: A Case Series Review
RU2522209C1 (en)Method of treating periodontitis

Legal Events

DateCodeTitleDescription
PUAIPublic reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text:ORIGINAL CODE: 0009012

17PRequest for examination filed

Effective date:20050811

AKDesignated contracting states

Kind code of ref document:A2

Designated state(s):AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RBVDesignated contracting states (corrected)

Designated state(s):AT DE FR GB IT

REGReference to a national code

Ref country code:DE

Ref legal event code:R079

Ref document number:60347762

Country of ref document:DE

Free format text:PREVIOUS MAIN CLASS: A61N0001300000

Ipc:A61K0009000000

A4Supplementary search report drawn up and despatched

Effective date:20110215

RIC1Information provided on ipc code assigned before grant

Ipc:A61K 9/00 20060101AFI20110209BHEP

Ipc:A61K 41/00 20060101ALI20110209BHEP

Ipc:A61N 1/30 20060101ALI20110209BHEP

17QFirst examination report despatched

Effective date:20111026

APBKAppeal reference recorded

Free format text:ORIGINAL CODE: EPIDOSNREFNE

APBNDate of receipt of notice of appeal recorded

Free format text:ORIGINAL CODE: EPIDOSNNOA2E

APBRDate of receipt of statement of grounds of appeal recorded

Free format text:ORIGINAL CODE: EPIDOSNNOA3E

APBVInterlocutory revision of appeal recorded

Free format text:ORIGINAL CODE: EPIDOSNIRAPE

RAP1Party data changed (applicant data changed or rights of an application transferred)

Owner name:BIOLITEC PHARMA IP & INVESTMENT LTD.

GRAPDespatch of communication of intention to grant a patent

Free format text:ORIGINAL CODE: EPIDOSNIGR1

INTGIntention to grant announced

Effective date:20150107

GRASGrant fee paid

Free format text:ORIGINAL CODE: EPIDOSNIGR3

GRAA(expected) grant

Free format text:ORIGINAL CODE: 0009210

AKDesignated contracting states

Kind code of ref document:B1

Designated state(s):AT DE FR GB IT

REGReference to a national code

Ref country code:DE

Ref legal event code:R081

Ref document number:60347762

Country of ref document:DE

Owner name:BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG, AT

Free format text:FORMER OWNER: CERAMOPTEC GMBH, 53121 BONN, DE

Ref country code:GB

Ref legal event code:FG4D

REGReference to a national code

Ref country code:AT

Ref legal event code:REF

Ref document number:733508

Country of ref document:AT

Kind code of ref document:T

Effective date:20150715

REGReference to a national code

Ref country code:DE

Ref legal event code:R096

Ref document number:60347762

Country of ref document:DE

REGReference to a national code

Ref country code:AT

Ref legal event code:MK05

Ref document number:733508

Country of ref document:AT

Kind code of ref document:T

Effective date:20150701

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:AT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20150701

REGReference to a national code

Ref country code:DE

Ref legal event code:R097

Ref document number:60347762

Country of ref document:DE

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:IT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20150701

PLBENo opposition filed within time limit

Free format text:ORIGINAL CODE: 0009261

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26NNo opposition filed

Effective date:20160404

REGReference to a national code

Ref country code:FR

Ref legal event code:PLFP

Year of fee payment:14

REGReference to a national code

Ref country code:DE

Ref legal event code:R082

Ref document number:60347762

Country of ref document:DE

Representative=s name:DENDORFER & HERRMANN PATENTANWAELTE PARTNERSCH, DE

Ref country code:DE

Ref legal event code:R081

Ref document number:60347762

Country of ref document:DE

Owner name:BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG, AT

Free format text:FORMER OWNER: BIOLITEC PHARMA IP & INVESTMENT LTD., LABUAN, MY

REGReference to a national code

Ref country code:GB

Ref legal event code:732E

Free format text:REGISTERED BETWEEN 20170629 AND 20170705

REGReference to a national code

Ref country code:FR

Ref legal event code:PLFP

Year of fee payment:15

PGFPAnnual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code:GB

Payment date:20170925

Year of fee payment:15

Ref country code:DE

Payment date:20170921

Year of fee payment:15

Ref country code:FR

Payment date:20170925

Year of fee payment:15

REGReference to a national code

Ref country code:DE

Ref legal event code:R119

Ref document number:60347762

Country of ref document:DE

GBPCGb: european patent ceased through non-payment of renewal fee

Effective date:20180911

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:DE

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20190402

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:FR

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20180930

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:GB

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20180911


[8]ページ先頭

©2009-2025 Movatter.jp